Overview

Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Status:
Active, not recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This research study is studying the combination of Atezolizumab and Bevacizumab as a possible treatment for Advanced Non-Clear Cell Kidney Cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Genentech, Inc.
Treatments:
Antibodies, Monoclonal
Atezolizumab
Bevacizumab